5-Amino-1MQ vs Liraglutide

Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms.

5-Amino-1-methylquinolinium (5-amino-1MQ) is a non-peptide small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation of nicotinamide using S-adenosyl methionine (SAM) as a methyl donor; NNMT is overexpressed in adipose tissue and has been identified as a metabolic regulator linking one-carbon metabolism, cellular methylation capacity, and adipogenesis. NNMT inhibition by 5-amino-1MQ is proposed to increase intracellular SAM and polyamine availability, shifting the cellular methylation balance in adipocytes toward suppression of adipogenesis and promotion of thermogenic gene expression; preclinical studies have examined effects on adipose tissue energy expenditure, systemic metabolism, and gut microbiome composition in diet-induced obesity mouse models. The best available indexed evidence is a preclinical study in diet-induced obese mice demonstrating that NNMT inhibition combined with caloric restriction altered microbiome composition and metabolic parameters; no human pharmacokinetic, safety, or efficacy data for 5-amino-1MQ has been published in any PubMed-indexed journal. 5-Amino-1MQ is a non-peptide research compound with no FDA approval or regulatory approval in any jurisdiction; it is not a peptide in the pharmacological sense and carries no human evidence base; all interest derives from preclinical metabolic data that has not been translated to human investigation. 5-Amino-1MQ dosage: No human clinical trial has established a dosing protocol for 5-Amino-1MQ. Preclinical research in rodent models has investigated this NNMT inhibitor at varying concentrations to assess metabolic effects. 5-Amino-1MQ is a research compound with no approved human dosing guidelines for any indication. Research protocols have explored oral and injectable delivery routes.

GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management and type 2 diabetes, formulated as a daily subcutaneous injection that reduces appetite by activating GLP-1 receptors in the hypothalamus and brainstem. It mimics endogenous incretin hormone action — slowing gastric emptying, increasing satiety signaling, and reducing caloric intake through central and peripheral GLP-1 receptor pathways. The landmark SCALE Obesity trial, a large multicenter randomized controlled trial published in the New England Journal of Medicine, demonstrated significant weight loss of approximately 8% at 56 weeks with 3.0 mg liraglutide (Saxenda) compared to placebo. Liraglutide is an FDA-approved prescription medication available as Victoza (type 2 diabetes, 1.8 mg) and Saxenda (chronic weight management, 3.0 mg); it requires physician supervision and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma. Liraglutide vs semaglutide: key distinctions Liraglutide is a daily subcutaneous injection; semaglutide is weekly. The dosing frequency difference reflects half-life: liraglutide's plasma half-life is approximately 13 hours, requiring daily administration to maintain therapeutic levels; semaglutide's albumin-binding modification extends its half-life to approximately 7 days. For weight management outcomes, semaglutide significantly outperforms liraglutide: STEP 1 reported ~15% mean weight reduction vs ~8% with liraglutide in SCALE. The practical implication is that liraglutide is generally appropriate for patients who have contraindications to once-weekly GLP-1 therapy, who are already established on liraglutide for T2D (Victoza), or who are in a jurisdiction where semaglutide is less accessible. Liraglutide has a longer post-approval safety record — it was approved in 2010 for T2D and 2014 for obesity management — while semaglutide's obesity indication was approved in 2021. The LEADER trial established cardiovascular risk reduction for liraglutide in T2D patients, adding an outcomes benefit beyond glucose control. Liraglutide cost and access: As a branded pharmaceutical (Victoza, Saxenda), liraglutide requires a prescription from a licensed provider. Saxenda (3.0mg/day for obesity) has an approximate monthly list price of $1,300–$1,500 USD; actual cost varies by insurance coverage and assistance programs. Generic or biosimilar liraglutide is not yet widely available in the US market. Compounding pharmacies do not commonly produce liraglutide formulations given the availability of approved branded products. Providers offering GLP-1 agonist programs that include liraglutide are searchable in the PeptideBase provider directory.